BAK NYSE Industrial Organic Chemicals Financials FY2016βFY2025
Braskem Sa had $12.6B of revenue in fiscal 2025, down 11.9% on the year before. Over five years, revenue changed +2.2% a year on average.
Last close Β· Oct 23, 2026
$1.70
6.3%Hi! I read Braskem Saβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β11.9%
No. Sales fell 11.9% last year.
Does it make a profit?
β14.0%
No. It lost money last year.
Does profit turn into cash?
β10.3%
No. It spent more cash than it brought in.
Is debt under control?
14.7x
Heavy. Repaying its debt would take 14.7 years of operating profit.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Braskem Sa did it, and the next one. Share prices often move a lot on those days.
Next results
November 10, 2026
Tuesday Β· in 16 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Apr 20, 2026 | Period ended Dec 31, 2025 | After the market closes | 20-F β |
| Mar 31, 2025 | Period ended Dec 31, 2024 | Time not announced | 20-F β |
| Apr 12, 2024 | Period ended Dec 31, 2023 | Before the market opens | 20-F β |
| Apr 25, 2023 | Period ended Dec 31, 2022 | Time not announced | 20-F β |
| Apr 28, 2022 | Q4 '21 | Time not announced | 20-F β |
| May 14, 2021 | Q4 '20 | Time not announced | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Braskem Sa had $12.6B of revenue in fiscal 2025, down 11.9% on the year before. Over five years, revenue changed +2.2% a year on average. Its operating margin was β2.6%, down 1.2Β pts: of every 100 in sales, about β3 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
KIRA Β· Braskem Sa lost $1.8B in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$1.3B in fiscal 2025, β10.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Braskem Sa owes $7.5B more than it holds in cash, about 14.7 years of operating profit.
Cash, debt and the ratios that show how comfortably Braskem Sa can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.6B | $2.4B | $2.9B | $2.4B | $1.9B |
| Debt incl. finance leases | $6.3B | $6.8B | $8.7B | $8.6B | $9.5B |
| Net debt / EBITDA | 0.8x | 2.5x | 12.0x | 8.6x | 14.7x |
| Debt / equity | 4.4x | 4.9x | 10.6x | β | β |
| Interest coverage | 5.3x | 0.8x | β0.5x | β0.2x | β0.3x |
| Current ratio | 1.6x | 1.4x | 1.5x | 1.3x | 0.8x |
| Quick ratio | 0.9x | 0.8x | 1.0x | 0.8x | 0.5x |
| Total assets | $16.6B | $16.7B | $18.9B | $16.4B | $14.9B |
| Total liabilities | $752M | $570M | $18.1B | $17.2B | $17.9B |
| Shareholders' equity | $1.4B | $1.4B | $823M | β$773M | β$2.9B |
| Net debt (β = net cash) | $4.7B | $4.4B | $5.8B | $6.2B | $7.5B |
KIRA Β· Its return on capital was β5.6%: every 100 invested in the business earned about β6 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
KIRA Β· Braskem Sa passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 6 / 9 | 6 / 9 | 4 / 9 | 3 / 9 | 8 / 8 | 2 / 8 | 2 / 8 | 4 / 8 | 2 / 8 |
| Accruals ratio | β8.8% | 2.8% | β11.3% | β7.6% | β15.0% | β0.9% | β10.8% | β2.6% | β14.5% | β6.5% |
| Altman Z'' | β | 1.20 | 0.93 | β | 0.24 | β | β | 0.68 | β0.01 | β2.05 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $13.7B | $15.4B | $15.9B | $13.3B | $11.4B | $19.6B | $18.7B | $14.1B | $14.4B | $12.6B |
| Gross profit | $3.6B | $4.1B | $3.1B | $1.6B | $2.2B | $5.9B | $2.2B | $605M | $1.1B | $278M |
| Research and development | $46.4M | $52.5M | $60.0M | $62.8M | $48.6M | $55.1M | $72.4M | $76.7M | $85.9M | $82.3M |
| Operating income | $1.7B | $2.9B | $2.3B | $39.0M | β$13.9M | $4.8B | $827M | β$559M | β$200M | β$323M |
| Interest expense | $702M | $696M | $822M | $984M | $953M | $909M | $980M | $1.1B | $1.3B | $1.2B |
| Pretax income | β$40.1M | $1.6B | $986M | β$1.2B | β$1.9B | $3.3B | $9.1M | β$1.2B | β$3.3B | β$509M |
| Income tax | $177M | $425M | $201M | β$498M | β$517M | $741M | $168M | β$261M | β$1.1B | $1.5B |
| Net income | β$118M | $1.2B | $773M | β$644M | β$1.3B | $2.6B | β$65.0M | β$917M | β$2.1B | β$1.8B |
| Net income to common | β$118M | $1.2B | $773M | β$644M | β$1.3B | $2.6B | β$65.0M | β$917M | β$2.1B | β$1.8B |
| Diluted EPS | β$0.30 | $3.04 | $1.94 | β$1.62 | β$3.26 | $6.52 | β | β | β | β |
| Diluted shares | 0.40B | 0.40B | 0.40B | 0.40B | 0.40B | β | β | β | β | β |
| Cash flow | ||||||||||
| Cash from operations | $1.3B | $771M | $2.5B | $574M | $1.2B | $2.7B | $1.7B | β$455M | $452M | β$751M |
| Capital expenditure | $741M | $712M | $740M | $680M | $535M | $634M | $938M | $907M | $698M | $553M |
| Free cash flow | $536M | $59.0M | $1.8B | β$106M | $685M | $2.1B | $794M | β$1.4B | β$246M | β$1.3B |
| Depreciation and amortization | β$768M | β$918M | $818M | $921M | $785M | $775M | $916M | $1.0B | $919M | $836M |
| Dividends paid | $573M | $313M | $410M | $170M | $0.5M | $1.1B | $261M | $1.4M | $1.1M | β |
| Dividends and buybacks | $573M | $313M | $410M | $170M | $0.5M | $1.1B | $261M | $1.4M | $1.1M | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $2.1B | $1.1B | $1.4B | $1.7B | $2.7B | $1.6B | $2.4B | $2.9B | $2.4B | $1.9B |
| Total debt | $7.2B | $7.1B | $6.4B | $7.2B | $8.0B | $6.3B | $6.8B | $8.7B | $8.6B | $9.5B |
| Current assets | $4.9B | $5.3B | $5.4B | $5.8B | $6.6B | $7.1B | $6.5B | $7.7B | $6.0B | $5.6B |
| Current liabilities | $7.0B | $5.6B | $5.9B | $4.0B | $5.5B | $4.5B | $4.6B | $5.0B | $4.6B | $7.3B |
| Inventory | $1.6B | $2.0B | $2.2B | $1.9B | $1.6B | $2.9B | $2.7B | $2.6B | $2.2B | $1.9B |
| Property and equipment, net | $9.1B | $9.0B | $8.2B | $8.0B | $6.9B | $6.7B | $7.1B | $7.9B | $6.5B | $6.9B |
| Intangible assets | $863M | $823M | $706M | $687M | $545M | $516M | β | β | β | β |
| Total assets | $15.9B | $15.9B | $15.2B | $16.9B | $16.6B | $16.6B | $16.7B | $18.9B | $16.4B | $14.9B |
| Total liabilities | $15.1B | $14.0B | $13.5B | $15.7B | $17.0B | $752M | $570M | $18.1B | $17.2B | $17.9B |
| Shareholders' equity | $841M | $1.9B | $1.7B | $1.2B | β$424M | $1.4B | $1.4B | $823M | β$773M | β$2.9B |
| Margins | ||||||||||
| Gross margin | 26.6% | 26.6% | 19.7% | 12.3% | 19.2% | 30.3% | 11.8% | 4.3% | 7.7% | 2.2% |
| Operating margin | 12.5% | 18.7% | 14.3% | 0.3% | β0.1% | 24.7% | 4.4% | β4.0% | β1.4% | β2.6% |
| EBITDA margin | 6.9% | 12.7% | 19.4% | 7.2% | 6.8% | 28.6% | 9.3% | 3.4% | 5.0% | 4.1% |
| Net margin | β0.9% | 7.8% | 4.9% | β4.9% | β11.4% | 13.2% | β0.3% | β6.5% | β14.6% | β14.0% |
| FCF margin | 3.9% | 0.4% | 11.3% | β0.8% | 6.0% | 10.8% | 4.3% | β9.6% | β1.7% | β10.3% |
| Returns | ||||||||||
| Return on capital | 22.6% | 27.4% | 27.0% | 0.5% | β0.2% | 61.4% | 9.3% | β6.7% | β2.9% | β5.6% |
| Return on capital employed | 19.2% | 28.0% | 24.4% | 0.3% | β0.1% | 39.9% | 6.8% | β4.0% | β1.7% | β4.2% |
| Return on equity | β14.0% | 88.3% | 43.1% | β44.5% | β328.0% | 524.9% | β4.7% | β83.1% | β8,487.0% | β |
| Return on assets | β0.7% | 7.6% | 5.0% | β4.0% | β7.7% | 15.6% | β0.4% | β5.2% | β11.9% | β11.3% |
| Return on tangible equity | β | 112.3% | 79.2% | β121.9% | β | 289.5% | β4.7% | β111.4% | β | β |
| Growth | ||||||||||
| Revenue growth | β | 13.0% | 2.8% | β16.4% | β14.4% | 72.5% | β4.6% | β24.4% | 1.7% | β11.9% |
| Net income growth | β | β | β36.2% | β183.3% | β | β | β102.5% | β | β | β |
| EPS growth | β | β | β36.0% | β183.3% | β | β | β | β | β | β |
| FCF growth | β | β89.0% | 2,930.9% | β105.9% | β | 207.5% | β62.3% | β271.5% | β | β |
| Share count change | β | 0.1% | β0.0% | β0.0% | 0.0% | β | β | β | β | β |
| Financial health | ||||||||||
| Net debt / EBITDA | 5.4x | 3.0x | 1.6x | 5.8x | 7.0x | 0.8x | 2.5x | 12.0x | 8.6x | 14.7x |
| Debt / equity | 8.5x | 3.7x | 3.8x | 5.9x | β | 4.4x | 4.9x | 10.6x | β | β |
| Interest coverage | 2.4x | 4.1x | 2.8x | 0.0x | β0.0x | 5.3x | 0.8x | β0.5x | β0.2x | β0.3x |
| Current ratio | 0.7x | 0.9x | 0.9x | 1.4x | 1.2x | 1.6x | 1.4x | 1.5x | 1.3x | 0.8x |
| Quick ratio | 0.5x | 0.6x | 0.6x | 1.0x | 0.9x | 0.9x | 0.8x | 1.0x | 0.8x | 0.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 5.4% | 4.6% | 4.7% | 5.1% | 4.7% | 3.2% | 5.0% | 6.4% | 4.9% | 4.4% |
| Payouts / FCF | 106.8% | 530.1% | 22.9% | β | 0.1% | 52.7% | 32.9% | β | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 6.0 | 6.0 | 4.0 | 3.0 | 8.0 | 2.0 | 2.0 | 4.0 | 2.0 |
| Altman Z'' | β | 1.2 | 0.9 | β | 0.2 | β | β | 0.7 | β0.0 | β2.1 |
| Accruals ratio | β8.8% | 2.8% | β11.3% | β7.6% | β15.0% | β0.9% | β10.8% | β2.6% | β14.5% | β6.5% |
Source: SEC EDGAR XBRL filings (CIK 0001071438). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in BRL under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. Per-share figures are per US-listed share (1 ADS = 2 ordinary shares). For information only β not investment advice. Check the original filings before relying on any figure.
